VERTEX PHARMACEUTICALS INC / MA Insider Trading for July 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VERTEX PHARMACEUTICALS INC / MA.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in VERTEX PHARMACEUTICALS INC / MA for July 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 90.29 | 3,437 | 310,327 | 10,313 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 91.05 | 6,445 | 586,817 | 14,180 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 109.14 | 3,867 | 422,044 | 16,758 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 96.87 | 3,437 | 332,942 | 10,313 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 83.36 | 3,437 | 286,508 | 860 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 45.11 | 8,438 | 380,638 | 0 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 48.74 | 4,500 | 219,330 | 0 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Option Exercise | M | 77.31 | 6,445 | 498,263 | 3,867 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 161.92 | 500 | 80,960 | 16,634 | 17.1 K to 16.6 K (-2.92 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 161.91 | 2,937 | 475,530 | 17,134 | 20.1 K to 17.1 K (-14.63 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Sell | S | 161.00 | 40,006 | 6,440,966 | 20,071 | 60.1 K to 20.1 K (-66.59 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 90.29 | 3,437 | 310,327 | 60,077 | 56.6 K to 60.1 K (+6.07 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 91.05 | 6,445 | 586,817 | 56,640 | 50.2 K to 56.6 K (+12.84 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 109.14 | 3,867 | 422,044 | 50,195 | 46.3 K to 50.2 K (+8.35 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 96.87 | 3,437 | 332,942 | 46,328 | 42.9 K to 46.3 K (+8.01 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 83.36 | 3,437 | 286,508 | 42,891 | 39.5 K to 42.9 K (+8.71 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 45.11 | 8,438 | 380,638 | 39,454 | 31 K to 39.5 K (+27.21 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 48.74 | 4,500 | 219,330 | 31,016 | 26.5 K to 31 K (+16.97 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Silva Paul M | SVP & Corp Controll ... | Buy | M | 77.31 | 6,445 | 498,263 | 26,516 | 20.1 K to 26.5 K (+32.11 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Option Exercise | M | 83.36 | 31,875 | 2,657,100 | 2,125 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Option Exercise | M | 77.31 | 55,250 | 4,271,378 | 12,750 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Option Exercise | M | 91.05 | 10,775 | 981,064 | 23,707 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Option Exercise | M | 96.87 | 25,500 | 2,470,185 | 8,500 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Sell | S | 162.40 | 200 | 32,480 | 115,888 | 116.1 K to 115.9 K (-0.17 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Sell | S | 161.71 | 5,106 | 825,691 | 116,088 | 121.2 K to 116.1 K (-4.21 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Sell | S | 161.01 | 2,000 | 322,020 | 121,194 | 123.2 K to 121.2 K (-1.62 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Sell | S | 159.61 | 815 | 130,082 | 123,194 | 124 K to 123.2 K (-0.66 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Sell | S | 158.62 | 1,829 | 290,116 | 124,009 | 125.8 K to 124 K (-1.45 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Sell | S | 157.56 | 400 | 63,024 | 125,838 | 126.2 K to 125.8 K (-0.32 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Sell | S | 161.00 | 123,400 | 19,867,400 | 126,238 | 249.6 K to 126.2 K (-49.43 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Buy | M | 83.36 | 31,875 | 2,657,100 | 249,638 | 217.8 K to 249.6 K (+14.64 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Buy | M | 77.31 | 55,250 | 4,271,378 | 217,763 | 162.5 K to 217.8 K (+34.00 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Buy | M | 91.05 | 10,775 | 981,064 | 162,513 | 151.7 K to 162.5 K (+7.10 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | SMITH IAN F | EVP, CFO & COO | Buy | M | 96.87 | 25,500 | 2,470,185 | 151,738 | 126.2 K to 151.7 K (+20.20 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Option Exercise | M | 77.31 | 20,000 | 1,546,200 | 21,250 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 162.07 | 1,564 | 253,477 | 90,710 | 92.3 K to 90.7 K (-1.69 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 161.44 | 4,461 | 720,184 | 92,274 | 96.7 K to 92.3 K (-4.61 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 160.04 | 500 | 80,020 | 96,735 | 97.2 K to 96.7 K (-0.51 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 158.90 | 1,300 | 206,570 | 97,235 | 98.5 K to 97.2 K (-1.32 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 158.05 | 800 | 126,440 | 98,535 | 99.3 K to 98.5 K (-0.81 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Sell | S | 161.00 | 20,000 | 3,220,000 | 99,335 | 119.3 K to 99.3 K (-16.76 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Sachdev Amit | EVP, CRO | Buy | M | 77.31 | 20,000 | 1,546,200 | 119,335 | 99.3 K to 119.3 K (+20.13 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 86.52 | 2,329 | 201,505 | 34,949 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Option Exercise | M | 90.29 | 8,500 | 767,465 | 25,500 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Sell | S | 161.00 | 10,829 | 1,743,469 | 28,809 | 39.6 K to 28.8 K (-27.32 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 86.52 | 2,329 | 201,505 | 39,638 | 37.3 K to 39.6 K (+6.24 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Parini Michael | EVP, CL&AO | Buy | M | 90.29 | 8,500 | 767,465 | 37,309 | 28.8 K to 37.3 K (+29.50 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Option Exercise | M | 48.74 | 73,750 | 3,594,575 | 44,250 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Option Exercise | M | 45.11 | 110,624 | 4,990,249 | 66,376 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 162.08 | 5,058 | 819,801 | 257,392 | 262.5 K to 257.4 K (-1.93 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 161.43 | 17,255 | 2,785,475 | 262,450 | 279.7 K to 262.5 K (-6.17 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 160.42 | 900 | 144,378 | 279,705 | 280.6 K to 279.7 K (-0.32 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 159.34 | 3,500 | 557,690 | 280,605 | 284.1 K to 280.6 K (-1.23 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 158.46 | 4,837 | 766,471 | 284,105 | 288.9 K to 284.1 K (-1.67 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 157.42 | 700 | 110,194 | 288,942 | 289.6 K to 288.9 K (-0.24 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Sell | S | 161.00 | 184,374 | 29,684,214 | 289,642 | 474 K to 289.6 K (-38.90 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Buy | M | 48.74 | 73,750 | 3,594,575 | 474,016 | 400.3 K to 474 K (+18.43 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | LEIDEN JEFFREY M | CEO & President | Buy | M | 45.11 | 110,624 | 4,990,249 | 400,266 | 289.6 K to 400.3 K (+38.19 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 109.14 | 32,343 | 3,529,915 | 25,157 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 96.87 | 6,303 | 610,572 | 6,875 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 162.04 | 1,336 | 216,485 | 114,424 | 115.8 K to 114.4 K (-1.15 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 161.38 | 3,464 | 559,020 | 115,760 | 119.2 K to 115.8 K (-2.91 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 159.85 | 400 | 63,940 | 119,224 | 119.6 K to 119.2 K (-0.33 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 158.92 | 1,000 | 158,920 | 119,624 | 120.6 K to 119.6 K (-0.83 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 158.08 | 700 | 110,656 | 120,624 | 121.3 K to 120.6 K (-0.58 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 161.00 | 39,833 | 6,413,113 | 121,324 | 161.2 K to 121.3 K (-24.72 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 109.14 | 32,343 | 3,529,915 | 161,157 | 128.8 K to 161.2 K (+25.11 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 96.87 | 6,303 | 610,572 | 128,814 | 122.5 K to 128.8 K (+5.14 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 81.54 | 20,000 | 1,630,800 | 0 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Option Exercise | M | 91.05 | 8,979 | 817,538 | 19,756 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Sell | S | 161.00 | 28,979 | 4,665,619 | 106,011 | 135 K to 106 K (-21.47 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 81.54 | 20,000 | 1,630,800 | 134,990 | 115 K to 135 K (+17.39 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | ALTSHULER DAVID | EVP, Global Researc ... | Buy | M | 91.05 | 8,979 | 817,538 | 114,990 | 106 K to 115 K (+8.47 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 131.89 | 2,125 | 280,266 | 17,000 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 91.05 | 10,775 | 981,064 | 23,707 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 131.89 | 14,875 | 1,961,864 | 19,125 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 109.14 | 38,250 | 4,174,605 | 38,250 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Option Exercise | M | 96.87 | 25,500 | 2,470,185 | 8,500 | |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 161.72 | 200 | 32,344 | 121,117 | 121.3 K to 121.1 K (-0.16 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 161.68 | 10,150 | 1,641,052 | 121,317 | 131.5 K to 121.3 K (-7.72 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 159.00 | 2,125 | 337,875 | 131,467 | 133.6 K to 131.5 K (-1.59 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 131.89 | 2,125 | 280,266 | 133,592 | 131.5 K to 133.6 K (+1.62 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 162.67 | 29,000 | 4,717,430 | 131,467 | 160.5 K to 131.5 K (-18.07 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Sell | S | 161.00 | 60,400 | 9,724,400 | 160,467 | 220.9 K to 160.5 K (-27.35 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 91.05 | 10,775 | 981,064 | 220,867 | 210.1 K to 220.9 K (+5.13 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 131.89 | 14,875 | 1,961,864 | 210,092 | 195.2 K to 210.1 K (+7.62 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 109.14 | 38,250 | 4,174,605 | 195,217 | 157 K to 195.2 K (+24.37 %) |
| Jul 21 2017 | VRTX | VERTEX PHARMACEUTI ... | Arbuckle Stuart A | EVP\Chief Commercia ... | Buy | M | 96.87 | 25,500 | 2,470,185 | 156,967 | 131.5 K to 157 K (+19.40 %) |
| Jul 19 2017 | VRTX | VERTEX PHARMACEUTI ... | SACHS BRUCE I | Director | Option Exercise | A | 0.00 | 317 | 0 | 5,592 | |
| Jul 19 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 96.87 | 573 | 55,507 | 13,178 | |
| Jul 19 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 130.96 | 100 | 13,096 | 122,511 | 122.6 K to 122.5 K (-0.08 %) |
| Jul 19 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 129.61 | 473 | 61,306 | 122,611 | 123.1 K to 122.6 K (-0.38 %) |
| Jul 19 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 96.87 | 573 | 55,507 | 123,084 | 122.5 K to 123.1 K (+0.47 %) |
| Jul 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Option Exercise | M | 73.51 | 3,438 | 252,727 | 6,875 | |
| Jul 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 128.57 | 1,216 | 156,341 | 122,511 | 123.7 K to 122.5 K (-0.98 %) |
| Jul 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Sell | S | 127.38 | 2,222 | 283,038 | 123,727 | 125.9 K to 123.7 K (-1.76 %) |
| Jul 06 2017 | VRTX | VERTEX PHARMACEUTI ... | Chodakewitz Jeffrey | EVP GMDA, CMO | Buy | M | 73.51 | 3,438 | 252,727 | 125,949 | 122.5 K to 125.9 K (+2.81 %) |